These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 28546261)
21. Randomised controlled trials: the importance of sample size. Sedgwick P BMJ; 2015 Mar; 350():h1586. PubMed ID: 25801454 [No Abstract] [Full Text] [Related]
22. Dynamic comparison of Kaplan-Meier proportions: monitoring a randomized clinical trial with a long-term binary endpoint. Brittain E; Follmann D; Yang S Biometrics; 2008 Mar; 64(1):189-97. PubMed ID: 17680830 [TBL] [Abstract][Full Text] [Related]
23. [New applications for individual participant data meta-analyses of randomized trials]. Lueza B; Lacas B; Pignon JP; Paoletti X Bull Cancer; 2017 Feb; 104(2):139-146. PubMed ID: 27908441 [TBL] [Abstract][Full Text] [Related]
24. Weighted Kaplan-Meier estimators for two-stage treatment regimes. Miyahara S; Wahed AS Stat Med; 2010 Nov; 29(25):2581-91. PubMed ID: 20799259 [TBL] [Abstract][Full Text] [Related]
25. Opportunity to increase life span in narrow QRS cardiac resynchronization therapy recipients by deactivating ventricular pacing: evidence from randomized controlled trials. Sohaib SM; Finegold JA; Nijjer SS; Hossain R; Linde C; Levy WC; Sutton R; Kanagaratnam P; Francis DP; Whinnett ZI JACC Heart Fail; 2015 Apr; 3(4):327-36. PubMed ID: 25770400 [TBL] [Abstract][Full Text] [Related]
26. Absolute benefit, number needed to treat and gain in life expectancy: which efficacy indices for measuring the treatment benefit? Kassai B; Gueyffier F; Boissel JP; Boutitie F; Cucherat M J Clin Epidemiol; 2003 Oct; 56(10):977-82. PubMed ID: 14568629 [TBL] [Abstract][Full Text] [Related]
27. A CACE for assessing non-compliance: Addressing non-compliance in randomised controlled trials. Simmons RA; Egger JR BJOG; 2019 Dec; 126(13):1558-1559. PubMed ID: 31222924 [No Abstract] [Full Text] [Related]
32. A causal proportional hazards estimator for the effect of treatment actually received in a randomized trial with all-or-nothing compliance. Loeys T; Goetghebeur E Biometrics; 2003 Mar; 59(1):100-5. PubMed ID: 12762446 [TBL] [Abstract][Full Text] [Related]
33. Bias and precision of measures of survival gain from right-censored data. Lamb KE; Williamson EJ; Coory M; Carlin JB Pharm Stat; 2015; 14(5):409-17. PubMed ID: 26218830 [TBL] [Abstract][Full Text] [Related]
34. How to read a Kaplan-Meier survival plot. Sedgwick P BMJ; 2014 Sep; 349():g5608. PubMed ID: 25216915 [No Abstract] [Full Text] [Related]
35. Issues in the planning and conduct of randomised trials. Bhandari M; Pape HC; Giannoudis PV Injury; 2006 Apr; 37(4):349-54. PubMed ID: 16487524 [TBL] [Abstract][Full Text] [Related]
36. Analysis of cluster randomised trials with an assessment of outcome at baseline. Hooper R; Forbes A; Hemming K; Takeda A; Beresford L BMJ; 2018 Mar; 360():k1121. PubMed ID: 29559436 [No Abstract] [Full Text] [Related]
37. Simultaneous group sequential analysis of rank-based and weighted Kaplan-Meier tests for paired censored survival data. Andrei AC; Murray S Biometrics; 2005 Sep; 61(3):715-20. PubMed ID: 16135022 [TBL] [Abstract][Full Text] [Related]
38. The role of censoring on progression free survival: oncologist discretion advised. Prasad V; Bilal U Eur J Cancer; 2015 Nov; 51(16):2269-71. PubMed ID: 26259493 [TBL] [Abstract][Full Text] [Related]